Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-27
    E.g., 2018-06-27

Articles

256683 items
12:00 AM, Oct 31, 1994  |  BioCentury | Finance

Back on The Street

Mabon Securities analyst Jacqueline Siegel produced her first report, an overview of the industry, since returning to Wall Street following her stint as CFO at Isis Pharmaceuticals Inc. It is clear, she said, that the...
12:00 AM, Oct 31, 1994  |  BioCentury | Strategy

Affymetrix's market focus

Affymetrix Inc., (Santa Clara, Calif.) leader of a consortium that last week was awarded a $31.5 million government grant to develop miniaturized DNA diagnostic systems, will focus on building high-tech tools for biomedical research and...
12:00 AM, Oct 31, 1994  |  BC Week In Review | Company News  |  Deals

Alza deal

Alza Corp. (AZA)   Nycomed Pharma (Oslo, Norway) will distribute AZA's nicotine transdermal patch in Austria, Belgium, Denmark, Finland, Greenland, Iceland, Luxembourg and the Netherlands. AZA expects the product to be introduced in Belgium, Denmark and...
12:00 AM, Oct 31, 1994  |  BC Week In Review | Company News  |  Deals

Ibex deal

BASF Bioresearch Corp. (Worcester, Mass.) will supply Phase III clinical quantities and future commercial quantities of Neutralase heparinase to IBEX (Montreal), which is preparing an IND for the product to neutralize heparin after bypass surgery....
12:00 AM, Oct 31, 1994  |  BioCentury | Strategy

Hillman's experimental CorBec

The virtual venture-backed company, built from Day One with a merger end point in mind, is starting to pop up here and there as a strategic option. The latest is a Hillman Medical Ventures startup, CorBec...
12:00 AM, Oct 31, 1994  |  BioCentury | Product Development

Land mine checklist

Commentary Land mine checklist As the descriptions of trials run by three companies demonstrated in last week's Commentary, the devil truly resides in the details of clinical trial planning and management. And despite the most...
12:00 AM, Oct 31, 1994  |  BioCentury | Regulation

The price of FDA's clinical trial plan

WASHINGTON - The FDA estimates that its proposed new rules to increase surveillance and reporting of adverse drug effects will cost drug sponsors and manufacturers some $24 million annually, although the rigor of its analysis...
12:00 AM, Oct 24, 1994  |  BioCentury | Politics, Policy & Law

'Reasonable pricing' spawns a conflict

WASHINGTON - The National Institutes of Health and Myriad Genetics Inc. said that a report last week in The Wall Street Journal exaggerated the intensity of a disagreement between the company and NIH over patent...
12:00 AM, Oct 24, 1994  |  BioCentury | Product Development

Trials & Tribulations

Commentary Trials & tribulations As industry watchers have no doubt noticed by now, this fall and beyond could be a critical juncture for the sector, as clinical milestones practically pile on top of one another....
12:00 AM, Oct 24, 1994  |  BioCentury | Product Development

Licking wounds from the clinic

Licking wounds from the clinic Disappointing pivotal data from Gensia Inc., ProCyte Corp. and Telios Pharmaceuticals Inc. illustrate the difficulties of replicating earlier successful studies. The importance of robust Phase II studies is again illustrated...

Pages